Epothilones in development for non-small-cell lung cancer: Novel anti-tubulin agents with the potential to overcome taxane resistance

Clinical Lung Cancer

Volumn 13, Issue 3, 2012, Pages 171-180

  Edelman, Martin J ^a   Shvartsbeyn, Marianna ^b  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

tubulin III; Anti tubulin agents; Epothilones; Lung cancer; Resistance

Indexed keywords

21 AMINOEPOTHILONE B; 9,10 DIDEHYDROEPOTHILONE D; BAY 86 5302; BETA TUBULIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPOTHILONE B; EPOTHILONE D; EPOTHILONE DERIVATIVE; GEMCITABINE; IXABEPILONE; NAVELBINE; PACLITAXEL; SAGOPILONE; TAXANE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ASTHENIA; CANCER RESISTANCE; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG MECHANISM; DRUG STRUCTURE; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; GENE OVEREXPRESSION; HUMAN; INJECTION SITE REACTION; LIMB PAIN; LUNG NON SMALL CELL CANCER; MYALGIA; NAUSEA; NEUROPATHIC PAIN; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; POLYNEUROPATHY; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

BRIDGED COMPOUNDS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; HUMANS; LUNG NEOPLASMS; TAXOIDS; TUBULIN MODULATORS;

EID: 84859874192     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.02.005     Document Type: Review

References (104)

1. Perez EA. Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 2009; 8:2086-95.
2. Borzilleri RM, Vite GD. Epothilones: new tubulin polymerization agents in preclinical and clinical development. Drugs Future 2002; 27:1149-63. (Pubitemid 36240777)
3. Giannakakou P, Gussio R, Nogales E, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A 2000; 97:2904-9. (Pubitemid 30159270)
4. Wartmann M, Altmann KH. The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents 2002; 2:123-48. (Pubitemid 34649871)
5. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4:253-65. (Pubitemid 38525281)
6. Giannakakou P, Sackett DL, Ward Y, et al. p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat Cell Biol 2000; 2:709-17.
7. Dumontet C, Sikic BI. Mechanisms of action and resistance to antitubulin agents: microtubule dynamics, drug transport and cell death. J Clin Oncol 1999; 17:1061-70 (Pubitemid 29109340)
8. Horwitz SB, Lothstein L, Manfradi JJ, et al. Taxol: mechanisms of action and resistance. Ann N Y Acad Sci 1986; 466:733-44. (Pubitemid 16012884)
9. Sullivan KF. Structure and utilization of tubulin isotypes. Annu Rev Cell Biol 1988; 4:687-716. (Pubitemid 19139269)
10. Burkhart CA, Kavallaris M, Band Horwitz S. The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 2001; 1471:1-9.
11. Luduena RF, Roach MC, Prasad V, et al. Interaction of halichondrin B and homohalichondrin B with bovine brain tubulin. Biochem Pharmacol 1993; 45:421-7. (Pubitemid 23042642)
12. Verdier-Pinard P, Wang F, Burd B, et al. Direct analysis of tubulin expression in cancer cell lines by electrospray ionization mass spectrometry. Biochemistry 2003; 42:12019-27 (Pubitemid 37280652)
13. Katsetos CD, Herman MM, Mork SJ. Class III beta-tubulin in human development and cancer. Cell Motil Cytoskeleton 2003; 55:77-96. (Pubitemid 36627260)
14. Falconer MM, Echeverri CJ, Brown DL. Differential sorting of beta tubulin isotypes into colchicine-stable microtubules during neuronal and muscle differentiation of embryonal carcinoma cells. Cell Motil Cytoskeleton 1992; 21:313-25.
15. Panda D, Miller HP, Banerjee A, et al. Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci U S A 1994; 91:11358-62. (Pubitemid 24356343)
16. Littauer UZ, Giveon D, Thierauf M, et al. Common and distinct tubulin binding sites for microtubule-associated proteins. Proc Natl Acad Sci U S A 1986; 83:7162-6. (Pubitemid 16000484)
17. Katsetos CD, Kontogeorgos G, Geddes JF, et al. Differential distribution of the neuron-associated class III beta-tubulin in neuroendocrine lung tumors. Arch Pathol Lab Med 2000; 124:535-44. (Pubitemid 30210985)
18. Katsetos CD, Del Valle L, Geddes JF, et al. Localization of the neuronal class III b-tubulin in oligodendrogliomas: comparison with Ki-67 proliferative index and 1p/19q status. J Neuropathol Exp Neurol 2002; 61:307-20. (Pubitemid 34266782)
19. Jirasek T, Pisarikova E, Viklicky V, et al. Expression of class III beta-tubulin in malignant epithelial tumours: an immunohistochemical study using TU-20 and TuJ-1 antibodies. Folia Histochem Cytobiol 2007; 45:41-5. (Pubitemid 46416519)
20. Seve P, Mackey J, Isaac S, et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005; 4:2001-7. (Pubitemid 43056983)
21. Ranganathan S, Benetatos CA, Colarusso PJ, et al. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 1998; 77:562-6. (Pubitemid 28059462)
22. Liu B, Staren ED, Iwamura T, et al. Mechanisms of taxotere related drug resistance in pancreatic carcinoma. J Surg Res 2001; 99:179-86. (Pubitemid 32703435)
23. Mozzetti S, Ferlini C, Concolino P, et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005; 11:298-305. (Pubitemid 40075808)
24. Kavallaris M, Kuo DY, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific b-tubulin isotypes. J Clin Invest 1997; 100:1282-93. (Pubitemid 27386315)
25. Kavallaris M, Burkhart CA, Horwitz SB. Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer 1999; 80:1020-5. (Pubitemid 29233923)
26. Khan IA, Ludueňa RF. Phosphorylation of beta III-tubulin. Biochemistry 1996; 35:3704-11.
27. Banerjee A, Roach MC, Trcka P, et al. Increased microtubule assembly in bovine brain tubulin lacking the type III isotype of β-tubulin. J Biol Chem 1990; 265: 1794-9.
28. Lu Q, Luduena RF. Removal of βIII isotype enhances taxol induced microtubule assembly. Cell Struct Funct 1993; 18:173-82. (Pubitemid 23307472)
29. Luduena RF. Multiple forms of tubulin: different gene products and covalent modifications. Int Rev Cytol 1998; 178:207-75. (Pubitemid 128717548)
30. Sharma J, Luduena RF. Use of N,N'-polymethylenebis(iodoacetamide) derivatives as probes for the detection of conformational differences in tubulin isotypes. J Protein Chem 1994; 13:165-76. (Pubitemid 24135981)
31. Kamath K, Wilson L, Cabral F, et al. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 2005; 280:12902-7.
32. Martello LA, Verdier-Pinard P, Shen HJ, et al. Elevated levels of microtubule destabilizing factors in a taxol-resistant/dependent A549 cell line with an α-tubulin mutation. Cancer Res 2003; 63:1207-13. (Pubitemid 36355832)
33. Carles G, Braguer D, Dumontet C, et al. Differentiation of human colon cancer cells changes the expression of beta-tubulin isotypes and MAPs. Br J Cancer 1999; 80:1162-8. (Pubitemid 29264075)
34. Laferriere NB, Brown DL. Expression and posttranslational modification of class III beta-tubulin during neuronal differentiation of P19 embryonal carcinoma cells. Cell Motil Cytoskeleton 1996; 35:188-99. (Pubitemid 26363865)
35. Alexander JE, Hunt DF, Lee MK, et al. Characterization of posttranslational modifications in neuron-specific class III b-tubulin by mass spectrometry. Proc Natl Acad Sci USA 1991; 88:4685-9. (Pubitemid 21914606)
36. Mary J, Redeker V, Le Caer JP, et al. Class I and IVa beta- tubulin isotypes expressed in adult mouse brain are glutamylated. FEBS Lett 1994; 353:89-94.
37. Lewis, SA, Gu W, Cowan NJ. Free intermingling of mammalian beta-tubulin isotypes among functionally distinct microtubules. Cell 1987; 49:539-48.
38. Izutsu N, Maesawa C, Shibazaki M, et al. Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells. Int J Oncol 2008; 32:1227-35.
39. Rosell R, Fossella F, Milas L; Spanish Lung Cancer Group. Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer. Lung Cancer 2002; 38(suppl 4):43-9.
40. Dumontet C, Isaac S, Souquet PJ, et al. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 2005; 92:E25-30.
41. Seve P, Mackey J, Isaac S, et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005; 4:2001-7. (Pubitemid 43056983)
42. Reiman T, Seve P, Vataire A, et al. Prognostic value of class III b-tubulin (TUBB3) in operable non-small cell lung cancer (NSCLC) and predictive value for adjuvant cisplatin-based chemotherapy (CT): a validation study on three randomized trials. J Clin Oncol 2008; 26(15 suppl):398s (abstract 7506).
43. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355:983-91. (Pubitemid 44343542)
44. Seve P, Isaac S, Tredan O, et al. Expression of class III b-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbinebased chemotherapy. Clin Cancer Res 2005; 11:5481-6. (Pubitemid 41060824)
45. Seve P, Lai R, Ding K, et al. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res 2007; 13:994-9. (Pubitemid 46340378)
46. Gan PP, Pasquier E, Kavallaris M. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 2007; 67:9356-63. (Pubitemid 47535925)
47. Jordan MA, Miller H, Ray A, et al. The Pat-21 breast cancer model derived from a patient with primary Taxol resistance recapitulates the phenotype of its origin, has altered b-tubulin expression and is sensitive to ixabepilone. Proc Am Assoc Cancer Res 2006; 47:73 (abstract LB-280).
48. Dumontet C, Jordan MA, Lee FF. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 2009; 8:17-25.
49. Lee MK, Tuttle JB, Rebhun LI, et al. The expression and posttranslational modification of a neuron-specific b-tubulin isotype during chick embryogenesis. Cell Mot Cytoskel 1990; 17:118-32. (Pubitemid 20372179)
50. Gygi SP, Rochon Y, Franza BR, et al. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 1999; 19:1720-30. (Pubitemid 29098230)
51. Chen G, Gharib TG, Wang H, et al. Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A 2003; 100:13537-42. (Pubitemid 37444777)
52. Gygi SP, Corthals GL, Zhang Y, et al. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc Natl Acad Sci U S A 2000; 97:9390-5. (Pubitemid 30650785)
53. Dozier JH, Hiser L, Davis JA, et al. Beta class II tubulin predominates in normal and tumor breast tissues. Breast Cancer Res 2003; 5:R157-69.
54. Bonnet C, Boucher D, Lazereg S, et al. Differential binding regulation of microtubule-associated proteins MAP1A, MAP1B, and MAP2 by tubulin polyglutamylation. J Biol Chem 2001; 276:12839-48.
55. Hiser L, Aggarwal A, Young R, et al. Comparison of beta-tubulin mRNA and protein levels in 12 human cancer cell lines. Cell Motil Cytoskeleton 2006; 63:41-52. (Pubitemid 43157644)
56. Yen TJ, Gay DA, Pachter JS, et al. Autoregulated changes in stability of polyribosome-bound b-tubulin mRNAs are specified by the first 13 translated nucleotides. Mol Cell Biol 1988; 8:1224-35.
57. Theodorakis NG, Cleveland DW. Physical evidence for cotranslational regulation of h-tubulin mRNA degradation. Mol Cell Biol 1992; 12:791-9.
58. Cleveland DW. Autoregulated control of tubulin synthesis in animal cells. Curr Opin Cell Biol 1989; 1:10-4. (Pubitemid 19174510)
59. Ling V. Charles F. Kettering Prize. P-glycoprotein and resistance to anticancer drugs. Cancer 1992; 69:2603-9.
60. Horwitz SB, Cohen D, Rao S, et al. Taxol: mechanisms of action and resistance. J. Natl Cancer Inst Monogr 1993; 15:55-61.
61. Cabral F. Factors determining cellular mechanisms of resistance to antimitotic drugs. Drug Resist Updat 2001; 4:3-8. (Pubitemid 32267819)
62. Roy S, Kenny E, Kennedy S, et al. MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in non-small cell lung cancer. Anticancer Res 2007; 27:1325-30. (Pubitemid 46807278)
63. Filipits M, Haddad V, Schmid K, et al. Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clin Cancer Res 2007; 13:3892-8 (Pubitemid 47037596)
64. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubulestabilizing agents with a taxol-like mechanism of action. Cancer Res 1995; 55:2325-33.
65. Hunt JT. Discovery of ixabepilone. Mol Cancer Ther 2009; 8:275-81.
66. Zhang CC, Yang JM, White E, et al. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene 1998; 16:1617-24. (Pubitemid 28159910)
67. Murphy M, Hinman A, Levine AJ. Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev 1996; 10:2971-80. (Pubitemid 26412524)
68. Kavallaris M, Tait AS, Walsh BJ, et al. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res 2001; 61:5803-9. (Pubitemid 32769098)
69. Cabral F, Wible L, Brenner S, et al. Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly. J Cell Biol 1983; 97:30-9. (Pubitemid 13076514)
70. Han EK, Gehrke L, Tahir SK, et al. Modulation of drug resistance by alphatubulin in paclitaxel-resistant human lung cancer cell lines. Eur J Cancer 2000; 36:1565-71. (Pubitemid 30619010)
71. Remmelink M, Mijatovic T, Gustin A, et al. Identification by means of cDNA microarray analyses of gene expression modifications in squamous non-small cell lung cancers as compared to normal bronchial epithelial tissue. Int J Oncol 2005; 26:247-58.
72. Duan Z, Feller AJ, Penson RT, et al. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxelresistant phenotype. Clin Cancer Res 1999; 5:3445-53.
73. Watson MB, Lind MJ, Cawkwell L. Establishment of in-vitro models of chemotherapy resistance. Anticancer Drugs 2007; 18:749-54. (Pubitemid 46975960)
74. Sanchez JM, Mellemgaard A, Perry M, et al. Efficacy and safety of patupilone in non-small cell lung cancer (NSCLC): a phase I/II trial. J Clin Oncol 2006; 24(suppl 18):390s (abstract 7104).
75. Zatloukal P, Mellemgaard A, Sanchez JM, et al. Activity of patupilone in advanced or metastatic non-small cell lung cancer (NSCLC): a phase II study. Ann Oncol 2008; 19(suppl 8):109 (abstract 296P).
76. Gatzemeier U, von Pawel J, Eschbach C, et al. Phase II trial of the novel epothilone ZK-EPO as second-line therapy in patients with stage IIIB or stage IV non-smallcell lung cancer. Eur J Cancer Suppl 2007; 5:378 (abstract 6568).
77. Fischer J R, von Pawel J, Schmittel A, et al. Phase II trial of sagopilone (ZK-EPO), a novel epothilone, as second-line therapy in patients with stage IIIb-IV non small cell lung cancer (NSCLC). Ann Oncol 2008; 19(suppl 8):viii110 (abstract 301P).
78. Delbaldo C, Lara PN, Vansteenkiste J, et al. Phase II study of the novel epothilone BMS-247550 in patients (pts) with recurrent or metastatic non-small cell lung cancer (NSCLC) who have failed first-line platinum-based chemotherapy. Proc Am Soc Clin Oncol 2002; 21:303a (abstract 1211).
79. Vansteenkiste J, Lara PN Jr, Le Chevalier T, et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 2007; 25:3448-55. Erratum: J Clin Oncol 2007; 25: 5339.
80. Rosell R, Scagliotti G, Danenberg KD, et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003; 22:3548-53. (Pubitemid 36765314)
81. Azuma K, Sasada T, Kawahara A, et al. Expression of ERCC1 and class III betatubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 2009; 64:326-33.
82. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350:351-60. (Pubitemid 38101630)
83. Gianni L. Ixabepilone and the narrow path to developing new cytotoxic drugs. J Clin Oncol 2007; 25:3389-91. (Pubitemid 47310871)
84. Borzilleri RM, Vite GD. Epothilones: new tubulin polymerization agents in preclinical and clinical development. Drugs Future 2002; 27:1149-63. (Pubitemid 36240777)
85. Schmid P, Kiewe P, Possinger K, et al. Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors. Ann Oncol 2010; 21:633-9.
86. Arnold D, Voigt W, Kiewe P, et al. Weekly administration of sagopilone (ZKEPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial. Br J Cancer 2009; 101:1241-7.
87. Rubin EH, Rothermel J, Tesfaye F, et al. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol 2005; 23:9120-9.
88. Ten Bokkel Huinink WW, Sufliarsky J, Smit WM, et al. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study. J Clin Oncol 2009; 27:3097-103.
89. Zhou Y, Zhong Z, Liu F, et al. KOS-1584: a rationally designed epothilone D analog with improved potency and pharmacokinetic (PK) properties. Proc Am Assoc Cancer Res 2005; 46: (abstract 2535).
90. Villalona-Calero M, Goel S, Schaaf L, et al. First-in-human phase I trial of a novel epothilone, KOS-1584. J Clin Oncol 2006; 24(18 suppl):79s (abstract 2003).
91. Beer TM, Higano CS, Saleh M, et al. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs 2007; 25:565-70.
92. Edelman MJ, Schneider C, Tsai C, et al. Randomized phase 2 study of ixabepilone plus carboplatin or paclitaxel plus carboplatin in β3 tubulin overexpressing nonsmall cell lung cancer. J Thorac Oncol 2010; 5 (12 suppl 1):S508 (abstract 20).
93. Roach CM, Tanna V, Welcher R, et al. Companion diagnostic test for expression of β-III tubulin in non-small cell lung cancer using an immunohistochemical assay in studies of ixabepilone. J Thorac Oncol 2010; 5 (12 suppl 1):S541 (abstract 186).
94. Yee L, Lynch T, Villalona-Calero M, et al. A phase II study of KOS-862 (epothilone D) as second-line therapy in non-small cell lung cancer. J Clin Oncol 2005; 23(16 suppl):652s (abstract 7127).
95. Michaud LB. The epothilones: how pharmacology relates to clinical utility. Ann Pharmacother 2009; 43:1294-309.
96. Sanchez JM, Mellemgaard A, Perry M, et al. Efficacy and safety of patupilone in non-small cell lung cancer (NSCLC): a phase I/II trial. J Clin Oncol 2006; 24(18 suppl):390s (abstract 7104).
97. Abrey L, Wen PY, Govindan R, et al. Activity of patupilone for the treatment of recurrent or progressive brain metastases in patients with non-small cell lung cancer: an open-label multicenter phase II study. J Clin Oncol 2007; 25(18 suppl): 688s (abstract 18058).
98. Gatzemeier U, von Pawel, Eschbach C, et al. Phase II trial of the novel epothilone ZK-EPO a second line therapy in patients with stage IIIb or stage IV non-small cell lung cancer. Eur J Cancer Suppl 2008; 5(4):378 (abstract 6568).
99. Kim JC, Kim JS, Saha D, et al. Potential radiation-sensitizing effect of semisynthetic epothilone B in human lung cancer cells. Radiother Oncol 2003; 68:305-13. (Pubitemid 38373434)
100. Hofstetter B, Vuong V, Broggini-Tenzer A, et al. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo. Clin Cancer Res 2005; 11:1588-96. (Pubitemid 40315244)
101. Tan AR, Mekhail T, Edelman MJ, et al. Phase I trial of ixabepilone administered as a 24-hour infusion in patients with advanced solid malignancies: updated safety and aximum tolerated dose. Eur J Cancer Suppl 2008; 6(12):131 (abstract 416).
102. Hoffmann J, Fichtner I, Lemm M, et al. Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases. Neuro Oncol 2009; 11:158-66.
103. Silvani A, Gaviani P, Fiumani A, et al. Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas. J Neurooncol 2009; 95:61-4.
104. Abrey LE, Wen P, Govindan R, et al. Patupilone for the treatment of recurrent/progressive brain metastases in patients with non-small cell lung cancer: an openlabel phase II study. J Clin Oncol 2008; 26(15 suppl):97s (abstract 2033).